Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teceleukin

Next Previous
X
Search
Drug Profile

Teceleukin

Alternative Names: BG 8301; Bioleukin; Bioleukin IL-2; Imunace; S 6820

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer
  • No development reported HIV infections
  • Discontinued Cancer metastases

Most Recent Events

  • 23 Feb 2005 Discontinued - Phase-II for Cancer metastases in Japan (Injection)
  • 23 Feb 2005 Discontinued - Preclinical for Cancer in South Korea (unspecified route)
  • 18 Nov 2003 No development reported - Clinical-Phase-Unknown for HIV infections treatment in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top